Page 1,290«..1020..1,2891,2901,2911,292..1,3001,310..»

Comparison of Spectrum Pharmaceuticals Inc. (SPPI) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – MS Wkly

Posted: November 5, 2019 at 6:46 am

Since Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership of both companies.

Valuation & Earnings

Table 1 highlights Spectrum Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows the return on equity, net margins and return on assets of the two firms.

Risk and Volatility

Spectrum Pharmaceuticals Inc. is 154.00% more volatile than Standard and Poors 500 due to its 2.54 beta. Competitively, Brainstorm Cell Therapeutics Inc.s beta is 1.19 which is 19.00% more volatile than Standard and Poors 500.

Analyst Ratings

The following table given below contains the ratings and recommendations for Spectrum Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.

The upside potential is 400.00% for Spectrum Pharmaceuticals Inc. with average target price of $41. Meanwhile, Brainstorm Cell Therapeutics Inc.s average target price is $9, while its potential upside is 131.96%. The data from earlier shows that analysts view suggest that Spectrum Pharmaceuticals Inc. seems more appealing than Brainstorm Cell Therapeutics Inc.

Institutional and Insider Ownership

Roughly 75.6% of Spectrum Pharmaceuticals Inc. shares are held by institutional investors while 11.4% of Brainstorm Cell Therapeutics Inc. are owned by institutional investors. Spectrum Pharmaceuticals Inc.s share held by insiders are 1.3%. Competitively, insiders own roughly 0.6% of Brainstorm Cell Therapeutics Inc.s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Spectrum Pharmaceuticals Inc. has -13.37% weaker performance while Brainstorm Cell Therapeutics Inc. has 12.96% stronger performance.

Summary

Spectrum Pharmaceuticals Inc. beats Brainstorm Cell Therapeutics Inc. on 8 of the 10 factors.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkins lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More:
Comparison of Spectrum Pharmaceuticals Inc. (SPPI) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly

Posted in Nevada Stem Cells | Comments Off on Comparison of Spectrum Pharmaceuticals Inc. (SPPI) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – MS Wkly

Transhumanism, AI, gaming and human biology to feature at Mumbrella MSIX with new session announced – mUmBRELLA*

Posted: November 5, 2019 at 6:41 am

Learn how transhumanism and artificial intelligence are changing the way we acquire users as software engineer for PALO IT and co-founder of Transhumanism Australia, Alyse Sue, speaks at Mumbrella MSIX to lift the lid on transhumanist technologies.

Sue, a full stack Node.js and C# software developer has co-founded three ventures focusing on health and emerging technology. Shes also had vast experience working with AI and blockchain and has previously spent nearly four years at KPMG focusing on finance and technology.

Sue will speak at Mumbrella MSIX on transhumanism and artificial intelligence

At Mumbrella MSIX, Sue will discuss using artificial intelligence to completely tailor content to passers-by, while also revealing how to target digital humans living in virtual worlds created by Facebook and other tech giants.

ADVERTISEMENT

In addition, shell uncover ways to plant messages directly in peoples brains using brain-computer-interfaces.

Also confirmed is Forethought group CEO, Ken Roberts, who will reveal how to avoid the big idea lottery. The former associate professor at Melbourne Business School and now managing partner of Forethought Research (formerly Roberts Research Group) will assert that there is still extreme ineffectiveness in advertising and that the origin of the issues is the intuition-based big idea.

Roberts will explain a scientifically proven way of forming a foundation for creative briefs and big ideas

He will share with delegates Prophecy Thoughts & Feelings, a scientifically proven, marketing science-based, method for identifying the rational and emotional motivations for category and brand-specific consumer behaviour and show how these motivational drivers should form the foundations of the creative brief and the big idea.

Meanwhile, Dr Juliette Tobias-Webb will lead an interactive session explaining the psychological reasons why consumers enjoy games and how certain structural characteristics of games elicit beliefs and behaviours that lead to continued engagement.

Tobias-Webb will reveal the real benefits of gaming and how it affects consumer thinking

Tobias-Webb, who has worked for Commonwealth Bank, Ogilvy & Mather and lectured at the University of Cambridge has spent her career focusing on understanding human behaviour and decision making and applying insight from neuroscience, psychology, and economics to create real-world, measurable behavioural change.

Curated by Adam Ferrier, consumer psychologist and chief thinker at Thinkerbell, Mumbrella MSIX (Marketing Sciences Ideas Xchange) explores the intersection of marketing, behavioural science, creativity, and everything in between.

It takes place on February 20 in Sydney with tickets on sale now.

Keep updated with Mumbrella MSIX by signing up to the newsletter

Read more here:
Transhumanism, AI, gaming and human biology to feature at Mumbrella MSIX with new session announced - mUmBRELLA*

Posted in Transhumanist | Comments Off on Transhumanism, AI, gaming and human biology to feature at Mumbrella MSIX with new session announced – mUmBRELLA*

Religious and spiritual online forums consist of chaotic, impactful ideas – Lamron

Posted: November 5, 2019 at 6:41 am

It was 3 a.m. on a typical Saturday in Geneseo. UHots was closing and there was nothing to domy alumni friend was visiting, so we trudged through the rain back to my place for an early morning catch-up. His life is a lot more exciting than mine, so I listened intently as he told me of his post-grad misadventures.

Did I ever tell you about the time I was almost recruited into a cult? he said casually. No, he had not. I listened intently as he told me of a private subreddit he had been added to and the pseudo-intellectual who ran the page, inviting people who had like-minded views to join.

This got me thinkingthis subreddit cant be the only page like this on the internet. Since then, I have uncovered similar communities and ideas (i.e. places where spiritual thought meets modern politics and personal musings) grasping for meaning in the digital age. I believe the new frontier for religious thought lies not in the worship spaces of yesteryear, but in online forums and other digital spaces where one can make their beliefs heard and gain a following.

Spiritual groups born and bred online occupy a space somewhere between absurdism and grave sincerity. There is a whole spectrum of those who believe, dont believe or are simply curious about a given sect of online spiritual thought.

In conducting research, I came across the website for The Church of Google, a parody religion founded in 2009 with the goal of creating commentary about the sophistication and increasing symbiotic relationship that technologies like Google play in our lives. I also came across online forums such as MySpiritualgroup, which is self-described as an online spiritual group which seeks to gather all genuine truth seekers from around the world and focuses on metaphysics and esoteric thought.

Additionally, there are countless Reddit forums, like the one my friend joined, focused on the interplay between religion and psychedelics, anarchy and the alt-rightto name a few topics that have been brought into the conversation via dedicated subreddits.

One of the most intriguing online spiritual movements is one called H+, or Transhumanism. According to H+pedia, an online Wikipedia-esque transhumanist encyclopedia, transhumanism can be defined as a belief or movement in favour of human enhancement, especially beyond current human limitations and with advanced technology such as artificial intelligence, life extension and nanotechnology.

While prescribers to the philosophy might describe themselves as post-religious, there is something fundamentally spiritual about their way of thinking, which combines the concept of human transcendence with modern technological advancement. I may add that transhumanists are the same people in favor of gene modifying and strong AI technology, as well as proponents of the concept of technological singularity.

The internet is chaos, and so it only makes sense that spiritual communities that have formed from the internet are chaotic as well. The wide range of content, from intellectual to idiotic, underscores the wide range of beliefs being vocalized. Not only have we been ushered into a new age with technology providing platforms to express opinions, but the very opinions themselves have also been altered and shifted due to the emergence of the internet and what that means for human development.

As spiritual discussion online continues to mold the worldviews of many internet users, it is important that we attempt to broaden our understanding of this emerging intellectual discourse in order to better understand its real-world implications.

You can call Hayley Jones a metamorphosis rock because they do well under pressure!

See more here:
Religious and spiritual online forums consist of chaotic, impactful ideas - Lamron

Posted in Transhumanist | Comments Off on Religious and spiritual online forums consist of chaotic, impactful ideas – Lamron

Stem Cell Therapy Market : Opportunities and Challenges – MENAFN.COM

Posted: November 4, 2019 at 1:42 am

(MENAFN - GetNews) Emerging countries (such as South Korea, India, and China) are supporting their respective domestic stem cell industry through various regulatory reforms that support commercialization and research activities related to stem cell therapy.

The globalstem cell therapy marketis estimated to reach USD 145.8 million by 2021, growing at a CAGR of 11.0% during the forecast period

Supportive regulations across developing countries

Emerging countries (such as South Korea, India, and China) are supporting their respective domestic stem cell industry through various regulatory reforms that support commercialization and research activities related to stem cell therapy.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48

Due to flexible policies regarding stem cell research, South Korea has made significant advancement in this industry. The less stringent and relatively fast approval process of clinical trials has enabled South Korean manufacturers to commercialize their stem cell therapy products. Researchers in the country have successfully developed stem cells that are a perfect genetic match to patients of all races, genders, and so forth. Due to progress in therapeutic cloning, they can efficiently produce stem cells tailored to the individual and with a low risk of immunological rejection.

The medical tourism industry in Mexico is growing rapidly. The country has been a popular destination for stem cell treatments. A significant number of Americans and Canadians travel to Mexico to avail lower-priced treatments that are unavailable in their countries due to regulatory policies. Many private companies in Mexico offer stem cell treatments. However, these treatments are not approved by the Federal Commission for the Protection against Sanitary Risk (COFEPRIS Mexican government regulatory authority for the manufacture and commercialization of drugs and medical products); they are also not considered as registered clinical trials. Yet, many of these treatments are offered as proven and effective therapies. COFEPRIS does not have standards or guidelines for evaluating, authorizing, and monitoring research and therapeutic activities involving human tissues and cells.

Many other developing countries have allowed the use of ESCs for R & D purpose.

n In March 2005, the Brazilian government passed a legislation that allows the use of in vitro fertilized embryos that have been frozen for more than three years.

n In India, it is permissible to establish new human ESC lines from spare embryos by obtaining approval from regulatory authorities.

n In China, regulatory guidelines (established in 2013) permit the use of embryos for stem cell research only if the embryos are obtained from in vitro fertilization (IVF); fetal cells from abortions; somatic cell nuclear transfer (SCNT); or voluntarily donated germ line cells.

Such supportive regulations across developing countries will provide significant growth opportunities for local as well as international players in the stem cell therapy market.

Technical limitations related to production scale-up

Due to technical difficulties faced at various manufacturing stages such as stem cell identification, isolation, storage, and preservation, it becomes difficult for a manufacturer to scale-up the production. Limited manufacturing capability for production scale-up is expected to hinder the large-scale manufacturing of stem cells. The scaling-up process is also affected due to the development process adopted during the research phase. Typically, less attention is paid to the scalability of production and the cost associated with it. Different stem cells require different environments for proliferation and differentiation, potentially including mechanical stimuli or flow conditions, variable gas tensions, chemical gradients, 3D frameworks, and supporting-cell paracrine signaling. These factors depend on the source and type of stem cell.

Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=48

There is a requirement for a basic stem-cell manufacturing solution which supports the production of a variety of stem cells and provides optimal environment. With current technological advancements, it is possible that a manufacturing solution can be programmed to control some factors; however, it is very difficult to provide a production system that fits all solutions. There are also concerns regarding the possibility of cells to adapt to different, more large-scale culture conditions while retaining safety and therapeutic efficacy. These limitations form a key challenge in the stem cell therapy market.

Browse Related Reports:

Cell Sorting Marketby Technology (FACS-based Droplet Sorting, MACS, Microfluidics), Product (Cell Sorters, Reagents, Consumables), Application (Research, Clinical), End User (Research Institutes, Biopharma Companies, Medical Schools) - Forecasts to 2021

3D Cell Culture Marketby Product (Scaffold-free (Hanging Drop, Bioreactor), Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell Research, Drug Discovery), End User (Pharmaceutical, Biotech, Research) - Global Forecast to 2022

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Media Contact Company Name: MarketsandMarkets Contact Person: Mr. Shelly Singh Email: Send Email Phone: 1-888-600-6441 Address: 630 Dundee Road Suite 430 City: Northbrook State: IL Country: United States Website: https://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

MENAFN3110201900703268ID1099205619

Go here to see the original:
Stem Cell Therapy Market : Opportunities and Challenges - MENAFN.COM

Posted in New Mexico Stem Cells | Comments Off on Stem Cell Therapy Market : Opportunities and Challenges – MENAFN.COM

Stem Cell Therapy: What’s Real and What’s Not at California’s For-Profit Clinics – UCSF News Services

Posted: November 3, 2019 at 12:51 am

Many for-profit stem cell clinics advertise therapies that are not backed by science and may actually cause harm.

For-profit stem cell clinics have popped up around California in recent years, advertising that they can treat everything from arthritis to Alzheimers, without FDA approval.

They claim that injections of stem cells (naturally occurring blank slate cells that can grow into any type of cell) can help alleviate pain or illness by replacing or regenerating diseased tissue claims that are not supported by existing research. The procedures can cost thousands of dollars out-of-pocket, and regulators have warned that patients have developed tumors, suffered infections and even lost eyesight after unapproved procedures.

No one knows how many clinics there are, but California reportedly has more than any other state. We asked Arnold Kriegstein, MD, PhD, director of the UC San Francisco Developmental & Stem Cell Biology Program, about whats real and whats not in stem cell medicine.

How do these clinics operate?

There has been an explosion of so-called clinics offering stem cell treatments for a wide range of ailments, none of which have been shown to be effective. They are largely unregulated. Many clinics claim that they can treat untreatable illnesses like Alzheimer's disease, autism, muscular dystrophy, or stroke. The list is quite extensive.

The majority are using fat tissue for their stem cells, obtained through liposuction. These are usually autologous cells, which means that they are taking the patient's own tissue and extracting cells to re-administer to the same patient, usually through an intravenous route. In addition to fat cells, some clinics administer bone marrow stem cells or umbilical cord or placental stem cells, which come from unrelated donors.

The clinics often advertise through testimonials from patients who've received their therapies. Many of the conditions that the testimonials address are the kinds that normally improve or fluctuate over time, such as joint pain, low back pain, arthritis, or multiple sclerosis.

The problem is that patients will receive a treatment, and then, within a month or two, they'll notice that the aches and pains in the joints are improving, and they will attribute the improvement to the stem cell therapy, when in fact it would've happened regardless.

What is the risk of trying an unproven stem cell treatment?

Reports of physical harm have included infections and the development of tumors. When using cells that are not the patients own, umbilical cord cells for example, immune responses can occur often triggering inflammatory conditions.

In cases where stem cells have been delivered into the eye, blindness has been reported, and when they have been delivered to the central nervous system through lumbar puncture (spinal tap), adverse outcomes including serious infections of the central nervous system and tumors have occurred.

Then there's the emotional cost associated with raising false hope, and the financial loss that comes from exorbitant fees charged for ineffective, potentially harmful therapies.

Why arent there more legitimate stem cell therapies available?

Stem cells have been in the news so much over the last decade or so that I think it has created the impression that therapies are already on the market. The reality is that it is very early days for the science. The most interesting, most promising animal studies are only now beginning to be translated into clinical trials, and the process for approval of therapies takes many years and very few are likely to succeed.

Unfortunately, the public needs to be patient, but the good news is that potential treatments are progressing along the pipeline.

What are some examples of proven stem cell therapies?

For the last 50 years or so, there have been countless patients successfully treated with hematopoietic stem cells, commonly known as bone marrow transplants. This remains the prototype for how a stem cell therapy can work. Other successful examples include corneal stem cell grafts for certain eye conditions, and skin grafts for burn victims.

There are efforts to see if stem cells could successfully treat diseases like Parkinson's and diabetes, particularly type 1 diabetes. There are clinical trials testing whether stem cell therapy might work against macular degeneration, a blinding disease that is very common as people age. There are also early stage clinical trials for nervous system disorders including stroke, spinal cord injury, and ALS (Lou Gehrigs disease).

All of these examples are still at a very early stage, where the primary goal is to make sure that the approaches are safe. To determine if they are effective will require large, well-controlled, relatively long-term clinical trials.

What will it take to advance stem cell therapy into more real treatments?

This is where basic research comes in. The field is evolving quickly, there's much to be done, and there's still a huge amount of promise in stem cell therapies down the road. But it's going to take a lot of very careful and very laborious research before we get there.

Go here to read the rest:
Stem Cell Therapy: What's Real and What's Not at California's For-Profit Clinics - UCSF News Services

Posted in Stem Cell Research | Comments Off on Stem Cell Therapy: What’s Real and What’s Not at California’s For-Profit Clinics – UCSF News Services

AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November – P&T Community

Posted: November 3, 2019 at 12:51 am

IRVINE, Calif., Nov. 1, 2019 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that it will be presenting at the following regenerative medicine and investor conferences in November:

Society for the Immunotherapy of Cancer (SITC) Annual MeetingOral PresentationPresenter: Dr. Daniela Bota, MD, PhD, University of California, Irvine; AIVITA GBM Principal InvestigatorTitle: Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastomaTime: November 6-10, 2019Location: Gaylord National Hotel & Convention Center, National Harbor, MD

The Regenerative Medicine Consortium of the Gulf Coast Consortia for Biomedical SciencesOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEOTitle: Clinical and Commercial Application of Scaled Human Stem Cell DerivatesTime: November 8, 4:00 PM CTLocation: Bioscience Research Collaborative, Houston, TX

NYC Oncology Investor ConferenceOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEO Title: AIVITA Corporate PresentationTime: November 12, 4:50 PM - 5:10 PMLocation: Rockefeller Center, New York, NY

Society for NeuroOncology Annual MeetingPoster PresentationTitle: Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma.Time: November 20-24, 2019Location: JW Marriott Desert Ridge, Phoenix, AZ

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of women with ovarian cancer.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aivita-biomedical-to-present-at-upcoming-regenerative-medicine-oncology-and-investor-conferences-in-november-300950053.html

SOURCE AIVITA Biomedical, Inc.

Continue reading here:
AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November - P&T Community

Posted in Stem Cell Research | Comments Off on AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November – P&T Community

Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) – MS Wkly

Posted: November 2, 2019 at 1:43 am

This is therefore a contrasting of the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Demonstrates Brainstorm Cell Therapeutics Inc. and HOOKIPA Pharma Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 represents Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK)s return on assets, return on equity and net margins.

Liquidity

1 and 1 are the respective Current Ratio and a Quick Ratio of Brainstorm Cell Therapeutics Inc. Its rival HOOKIPA Pharma Inc.s Current and Quick Ratios are 5.6 and 5.6 respectively. HOOKIPA Pharma Inc. has a better chance of clearing its pay short and long-term debts than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

Ratings and Recommendations for Brainstorm Cell Therapeutics Inc. and HOOKIPA Pharma Inc. can be find in next table.

Brainstorm Cell Therapeutics Inc. has a consensus price target of $9, and a 140.00% upside potential. On the other hand, HOOKIPA Pharma Inc.s potential upside is 124.82% and its consensus price target is $18.75. The information presented earlier suggests that Brainstorm Cell Therapeutics Inc. looks more robust than HOOKIPA Pharma Inc. as far as analyst belief.

Institutional & Insider Ownership

The shares of both Brainstorm Cell Therapeutics Inc. and HOOKIPA Pharma Inc. are owned by institutional investors at 11.4% and 35.9% respectively. Insiders owned roughly 0.6% of Brainstorm Cell Therapeutics Inc.s shares. Comparatively, insiders own roughly 0.9% of HOOKIPA Pharma Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc. had bullish trend while HOOKIPA Pharma Inc. had bearish trend.

Summary

On 6 of the 11 factors Brainstorm Cell Therapeutics Inc. beats HOOKIPA Pharma Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View original post here:
Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) - MS Wkly

Posted in New Jersey Stem Cells | Comments Off on Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) – MS Wkly

Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)’s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)’s results – MS Wkly

Posted: November 2, 2019 at 1:43 am

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

In table 1 we can see Brainstorm Cell Therapeutics Inc. and Pieris Pharmaceuticals Inc.s top-line revenue, earnings per share and valuation.

Profitability

Table 2 represents Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)s return on equity, return on assets and net margins.

Volatility & Risk

A beta of 1.19 shows that Brainstorm Cell Therapeutics Inc. is 19.00% more volatile than Standard and Poors 500. Competitively, Pieris Pharmaceuticals Inc.s 21.00% volatility makes it more volatile than Standard and Poors 500, because of the 1.21 beta.

Liquidity

Brainstorm Cell Therapeutics Inc.s Current Ratio and Quick Ratio are 1 and 1 respectively. The Current Ratio and Quick Ratio of its competitor Pieris Pharmaceuticals Inc. are 3 and 3 respectively. Pieris Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Brainstorm Cell Therapeutics Inc.

Analyst Ratings

The Recommendations and Ratings for Brainstorm Cell Therapeutics Inc. and Pieris Pharmaceuticals Inc. are featured in the next table.

Brainstorm Cell Therapeutics Inc. has a consensus target price of $9, and a 140.00% upside potential. Competitively Pieris Pharmaceuticals Inc. has a consensus target price of $5, with potential upside of 45.77%. The data from earlier shows that analysts view suggest that Brainstorm Cell Therapeutics Inc. seems more appealing than Pieris Pharmaceuticals Inc.

Insider and Institutional Ownership

The shares of both Brainstorm Cell Therapeutics Inc. and Pieris Pharmaceuticals Inc. are owned by institutional investors at 11.4% and 61.7% respectively. About 0.6% of Brainstorm Cell Therapeutics Inc.s share are held by insiders. On the other hand, insiders held about 0.23% of Pieris Pharmaceuticals Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc. has weaker performance than Pieris Pharmaceuticals Inc.

Summary

On 8 of the 11 factors Pieris Pharmaceuticals Inc. beats Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases. It has strategic partnership agreements with Allergan, Inc.; Sanofi Group; Daiichi Sankyo Company Limited; F.Hoffmann- La Roche Ltd. and Hoffmann- La Roche Inc.; ASKA Pharmaceutical Co., Ltd; and Les Laboratoires Servier and Institut de Recherches Internationales. The company also has a research and licensing agreement with Technische Universitt Mnchen; and a collaboration agreement with AstraZeneca. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more here:
Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)'s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)'s results - MS Wkly

Posted in New Jersey Stem Cells | Comments Off on Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)’s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)’s results – MS Wkly

Reviewing ImmunoGen Inc. (IMGN)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

Posted: November 2, 2019 at 1:43 am

This is therefore a contrasting of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in ImmunoGen Inc. (NASDAQ:IMGN) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Table 1 demonstrates ImmunoGen Inc. and Brainstorm Cell Therapeutics Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of ImmunoGen Inc. and Brainstorm Cell Therapeutics Inc.

Volatility & Risk

ImmunoGen Inc. has a 2.28 beta, while its volatility is 128.00%, thus making it more volatile than Standard & Poors 500. In other hand, Brainstorm Cell Therapeutics Inc. has beta of 1.19 which is 19.00% more volatile than Standard & Poors 500.

Liquidity

The Current Ratio of ImmunoGen Inc. is 4.7 while its Quick Ratio stands at 4.7. The Current Ratio of rival Brainstorm Cell Therapeutics Inc. is 1 and its Quick Ratio is has 1. ImmunoGen Inc. is better equipped to clear short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Ratings

ImmunoGen Inc. and Brainstorm Cell Therapeutics Inc. Recommendations and Ratings are available in the next table.

Brainstorm Cell Therapeutics Inc. on the other hand boasts of a $9 average target price and a 140.64% potential upside.

Insider & Institutional Ownership

Roughly 80.3% of ImmunoGen Inc. shares are held by institutional investors while 11.4% of Brainstorm Cell Therapeutics Inc. are owned by institutional investors. Insiders held roughly 0.6% of ImmunoGen Inc.s shares. On the other hand, insiders held about 0.6% of Brainstorm Cell Therapeutics Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year ImmunoGen Inc. had bearish trend while Brainstorm Cell Therapeutics Inc. had bullish trend.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companys product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Original post:
Reviewing ImmunoGen Inc. (IMGN)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly

Posted in New Jersey Stem Cells | Comments Off on Reviewing ImmunoGen Inc. (IMGN)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

On Stage: Allegaeon ready to rock Philly – The Unionville Times

Posted: November 2, 2019 at 1:43 am

By Denny Dyroff, Entertainment Editor, The Times

Allegaeon

Whenever Allegaeon comes to the area for a show, metal music fans get excited.

Allegaeon plays a smorgasbord of metal music that rattles the rafters and usually tours on a bill with several top-flight metal acts.

When Allegaeon played the Voltage Lounge last year, the band was on a bill that included Rings of Saturn, Entheos, Neckrogoblikon, Lorna Shore and Gloom.

On October 31, Allegaeon will bring its Apoptosis Tour Pt II to MilkBoy Philly (1100 Chestnut Street, Philadelphia, 215- 925-6455, http://www.milkboyphilly.com). The show will also include a trio of opening acts Paladin, Inferi and IATT.

The current line-up of Allegaeon features Greg Burgess, lead guitar (2008present); Michael Stancel, rhythm guitar (2013present); Brandon Park, drums (2013present); Riley McShane, vocals (2015present); and Brandon Michael, bass (2017present).

Allegaeon has released five albums Fragments of Form and Function (2010), Formshifter (2012), Elements of the Infinite (2104), Proponent for Sentience (2016), and Apoptosis (2109). All five are on Metal Blade Records.

Judging by the album titles, this is not a typical gloom metal band singing about anger-fueled rebellion, animal mutilation or the impending end of the world.

Allegaeon plays a wide variety of styles mostly within the realm of metal music. The band plays death metal and incorporates technical expertise and a sense of melody without sacrificing the heaviness inherent in death metal.

Listeners can hear many influences, including prog-rock, thrash metal, classical music and prog-metal. Lyrical themes are both heavy and intellectual stem cell research, alien life, evolution, physics, artificial intelligence, cryonic experimentation and biology.

Were a melodic death metal band that experiments with a lot of different genres and influences, said McShane, during a phone interview Monday afternoon. Theres something for everyone.

With Allegaeon, a lot of metal fans can find something to identify with. Our song structure is pretty straightforward. Technical fans also can find a lot to like. But the foundation is always death metal.

Apoptosis dropped in April and the band has been touring ever since.

We recorded the album in November and December last year, said McShane. We tracked at Flatline Audio in Denver with producer Dave Otero. Weve always worked with Dave. Hes a phenomenal engineer.

We approached the writing differently with this album. The writing was different because we were on the road. So, it was more organinc and less formulaic. Instead of trying to write an album, we just wrote.

The result was that the band wrote a powerful album with songs that fit together perfectly.

According to McShane, Thematically, this record is all about contrast, and the music reflects that perfectly. The vocals are heavier than ever, but there are also more clean sections. The drums are faster than ever but also more dynamic, and the guitar playing is lower and slower than on most previous albums, but also provides long, melodic and beautiful sections throughout.

Allegaeon got its start in northern Colorado in 2008.

Were still based out of Denver, said McShane I live in Escondido, California, our drummer lives in Illinois and our bassist lives in Northern California. But Denver remains our home base.

I was living in Santa Cruz and was in a band called Son of Aurelius and we had an album that was Gregs favorite album ever. Allegaeon needed a vocalist so Greg hit me up.

With every member change, the foundation of Allegaeons sound is kept intact but each new member brings something new to the table. I was really excited when Brandon Michael joined the band because he has such a versatile bass style.

The definition of the word, apoptosis, is the death of cells which occurs as a normal and controlled part of an organisms growth or development.

Our album Apoptosis is all about new cells replacing old cells, said McShane. Its the idea of the old with the new. Its about how weve grown over the years. There are also lyrical themes of science like weve always used.

We took the music in a heavier direction but also in a more melodic direction while maintaining the same strengths weve always had.

But you have to be careful. You cant take to many hard-left turns. You dont want to lose old fans, and, at the same time, you dont want to make the same album over and over again.

But, like I said, the foundation is always death metal melodic and technical. I dont think that will ever change.

Video link for Allegaeon https://youtu.be/UfwkhX803JI?list=PL287EF95A4FFE743F.

Paladin

Paladin, which is billed as a power metal band, is a hard-hitting quartet featuring Taylor Washington, Guitar/Vocals; Alex Parra, Guitar; Andy McGraw, Bass/Vocals; and Nathan McKinney, Drums.

The band, which formed in 2015 in Atlanta, just released its debut album, Ascension, a few months ago on Prosthetic Records.

Ascension immediately entered the U.S. Billboard charts upon its May 17 release at the following positions Billboard Hard Music Albums #35; BillboardTop New Artists Album #40; BillboardIndependent Albums #88; and Billboard Digital Albums #182.Incorporating an array of influences from 1980s metal to melodic death metal into its blend of power thrash, Paladin is on a mission to bring some European flavor to the US metal scene with Ascension.

This is our first tour in support of the album and our first real tour in general, said Washington, during a phone interview Monday from a tour stop in Orlando, Florida. We went on a short run in August. And, we played ProgPower this year.

ProgPower USA is a progressive, power metal, and progressive rock festival held annually in the United States since 2001. Its most recent edition, ProgPower USA XX, was held at Center Stage in Atlanta, Georgia from September 4-7, 2019. Paladin is now on a 17-day nationwide tour.

We recorded Ascension at Matt Smith at Theocracized Studios in Athens, Georgia. The studio belongs to Matt Smith, who is in a band called Theocracy. We co-produced the album with Matt and then he mixed and mastered it.

Matt, who is Theocracys vocalist, plays keyboards and guitar. He is a great producer and a great musician. And his style of music is similar to ours.

Paladin has its roots in Atlanta in 2015 when Washington and Parra were looking for a new vehicle for their music.

Paladin came from the ashes of another band in Atlanta, said Washington. I was playing guitar and Alex was playing bass in a metal band called Sybaritic.

That band broke up and some of us kept going as Paladin. I started doing vocals and Alex switched to guitar. That was four-and-a-half years ago. Weve gone through two lineup changes since then. Nate has now been our drummer for four years and we have a new bass player.

Paladin now has a stable line-up and a well-received new album.

Certain thematic elements run through the album, said Washington. There is the theme of duality light vs. darkgood vs. evil. There is also a running theme of positivity and perseverance.

Video link for Paladin https://youtu.be/U_X2L2ixbXA.

The show at MilkBoy Philly, which features Allegaeon, Paladin, Inferi and IATT, will start at 7:30 p.m. Tickets are $18.

Othr upcoming shows at MilkBoy Philly are American Dinosaur and Sun Parade on November 1, Adam Flymo Birch and the Vershions on November 2, Funk You on November 3, Ida Mae on November 4, JJ Wilde on November 5, and Blockhead on November 6.

Huntertones

Huntertones is a high energy horn-driven group founded in Columbus, Ohio and currently based in Brooklyn, New York. On October 31, Huntertones will be sharing the bill with Great Time at World Caf Live (3025 Walnut Street, Philadelphia, 215-222-1400, http://www.worldcafelive.com).

The bands signature sound is a marriage of inspired improvisation and adventurous compositions that meld jazz, funk, soul, hip-hop, R&B, and rock. In addition to covering a wide range of genres, the versatile group is known for the ability to shift from a dynamic six-piece ensemble to an unconventional trio featuring saxophone, sousaphone, and beat-boxing.

The current Huntertones line-up features Dan White, Saxophones; Jon Lampley, Trumpet/Sousaphone; Chris Ott, Trombone/Beatbox; Josh Hill, Guitar; John Hubbell, Drums; and Adam DeAscentis, Bass.

We tour the states pretty regularly festivals, rock rooms, jazz clubs, said White, during a phone interview last week from his home in Brooklyn.

When Huntertones play shows in Michigan, a bit of caution is needed on the part of the band.

The biggest and most intense rivalry in major college football is the one between the University of Michigan and The Ohio State University. The Philadelphia Eagles-Dallas Cowboys rivalry pales in comparison.

The members of Huntertones met at The Ohio State University and got their start playing house shows at their Hunter Avenue apartment.

Chris and Jon were both in The Ohio State University Marching Band, said White.

This fall, we collaborated with The Ohio State University Marching Band. They played one of our songs in their show. It was a tribute to our song Togo, which is on our latest album.

Were all very aware of the intensity of the rivalry between the two schools. When we were still in Columbus, if we had shows in Michigan, wed just say that we were a band from Ohio. If we were playing Ann Arbor, we definitely didnt want to bring up our connection to Ohio State. Now, weve been living in Brooklyn for five years.

The band started 2016 with a month-long tour of North America, South America, and Africa through the American Music Abroad program. They were selected by the U.S. Department of State and the Bureau of Educational and Cultural Affairs to engage international audiences, students, and artists from around the globe.

When we moved to New York, we hooked up with American Music Abroad, said White. One of our first countries was Togo. Weve done three tours with them altogether and we have another coming up this January. On our own, weve toured Japan, China and South Korea. And, weve spent the last two summers touring Europe.

Considering all the travel Huntertones has done, it made sense to call the new album, Passport.

All the international touring was inspiration for our latest album, said White, who is a native of Buffalo, New York. We picked up stylistic influences coming from different places. We were also influenced by the stories.

We recorded Passport in Jersey City at Kaleidoscope Sound. It has a nice big main room and that allowed us to play together live in one space. We recorded it December 2017 and released it last fall.

Were releasing a new single on November 8 called Disco Tent. We recorded the track when we were out on tour. Well be going into the studio to record our next album soon.

Video link for Huntertones https://youtu.be/KRu6wugevy0.

The show at the World Caf Live, which also features Great Time, will start at 8 p.m. Tickets are $12.

Other upcoming shows at the venue are The John Byrne Band Album Release Show on November 1, Superchunk on November 5 and Brendan James on November 6.

Come from Away

Now through November 3, the hit musical Come from Away is being presented at the Academy of Music (Broad and Locust streets, Philadelphia, 215-731-3333,www.kimmelcenter.org) as part of the Kimmel Centers Broadway Philadelphia series.

The musical Come from Away is the uplifting and true story of 7,000 stranded passengers and the people of Gander, Newfoundland, the small Canadian town that welcomed them. Cultures clashed and nerves ran high, but uneasiness turned into trust, music soared into the night, and gratitude grew into enduring friendships.

It is set in the week following the September 11 attacks and tells the true story of what transpired when 38 planes were ordered to land unexpectedly in the small town of Gander in the province of Newfoundland and Labrador, Canada, as part of Operation Yellow Ribbon.

The characters in the musical are based on (and in most cases share the names of) real Gander residents as well as some of the thousands of stranded travelers they housed and fed.

The music in the show is a marriage of history and culture in Newfoundland. Its also married to a traditional Broadway sound.

Video link for Come from Away https://youtu.be/Nwm1IVAbnXk.

Come from Away is running now through November 3 at the Academy of Music. Ticket prices range from $20-$139.

Vassal

Kennett Flash (102 Sycamore Alley, Kennett Square, 484-732-8295,http://www.kennettflash.org) will have LENNON LIVE A Tribute to John Lennon on November 1 and Open Mic with Vassal on November 3.

The Steel City Coffee House (203 Bridge Street, Phoenixville, 610-933-4043, http://www.steelcitycoffeehouse.com) will host The Beatles Breadbasket on November 1 and Rofo Audio with Roi and the Secret People on November 2.

Chaplins (66 North Main Street, Spring City, 610-792-4110,http://chaplinslive.com) will host Haxon, Pandemic, Relapsed, and Tachyon on November 1 and Steve Zinno, Nick Filone, and Ralph Pagano on November 2.

Living Room (35 East Lancaster Avenue, Ardmore, https://thelivingroomat35east.com) will host Hot Club of Philadelphia on November 1 and The Peace Creeps on November 2.

The Ardmore Music Hall (23 East Lancaster Avenue, Ardmore, 610-649-8389,www.ardmoremusic.com) will present Splintered Sunlight on October 31, Philly Bloco on November 1, Aztec Two Step on November 2, Live Dead 69 featuring Tom Constanten plus members of Ratdog, Jefferson Starship on November 3, and Trigger Hippy on November 6.

Burlap & Bean Coffeehouse (204 South Newtown Street Road, Newtown Square, 484-427-4547,www.burlapandbean.com) will host Vilebred on November 1.

118 North (118 North Wayne Avenue, Wayne, http://www.118northwayne.com) will host Atlas Gray on November 1 and Dead Friends on November 2.

The Locks at Sona (4417 Main Street, Manayunk, 484- 273-0481, sonapub.com) will have Joseph Arthur on November 1, and Susan Werner with special guest Vanida Gail on November 2 and 3.

The Keswick Theater (291 N. Keswick Avenue, Glenside, 215-572-7650,www.keswicktheatre.com) presents The Hooters on November 1 and 2 and Home Free on November 6.

Annenberg Center (3680 Walnut Street, Philadelphia, https://annenbergcenter.org/events) will present Vox Luminis on November 1.

The Sellersville Theater (24 West Temple Avenue, Sellersville, 215-257-5808,www.st94.com) will have Swing That Cat on October 31, Tom Cotter on November 1, Marcia Ball on November 2, Arrival from Sweden: Music of Abba on November 3, Adrian Legg & Laurence Juber on November 4, All Star Tribute to the Flying Burrito Brothers on November 5, and The Outlaws on November 6.

The Grand Opera House (818 North Market Street, Wilmington, Delaware, 302-652-5577, http://www.thegrandwilmington.org) will present Home Free on November 1.

Read this article:
On Stage: Allegaeon ready to rock Philly - The Unionville Times

Posted in New Jersey Stem Cells | Comments Off on On Stage: Allegaeon ready to rock Philly – The Unionville Times

Page 1,290«..1020..1,2891,2901,2911,292..1,3001,310..»